• 대한수의학회지
• /
• 제35권3호
• /
• pp.481-488
• /
• 1995

In oriental folk medicine, Artemisia messes-schmidiana var viridis(Compositae) has been used for jaundice, hepatitis, diuretic and liver cirrhosis etc. 1-naphthylisothiocyanate(ANIT) has been used for more than 20 years as a model compound to study mechanisms of intrahepatic cholestasis in laboratory animals as rat and mouse. Various biochemical and morphological changes including biliary epithelial and parenchymal cell necrosis occur in the liver of animals treated with ANIT. The purposes of present study are to examine pharmacological effects of Artemisia messes-schmidiana var viridis water extract(AMWE) on alterations of secretion volume and total bile acids level in bile juice, and that of serum AST, ALT, ALP, bilirubin, and glucose levels in rat. AMWE stimulated bile secretion and recovered ANIT-induced cholestasis. Bile acid concentrations increased to more than 60% compared with normal by ANIT, which were returned toward normal value with AMWE treatment. Serum AST and ALT activities were increased by ANIT and yet which were significantly decreased with AMWE treatment. In addition, this effect was apparent in AMWE pretreatment group. Serum glucose levels were increased with AMWE and ANIT, while were decreased compared with control in AMWE posttreatment group. Increased serum total bilirubin contents and ALP activities by ANIT were significantly decreased with AMWE posttreatment. In conclusion, AMWE exerted bile acid-independent choleresis effect and then improved to normal conditions ANIT-induced cholestatic syndromes. Also, AMWE have protective and regenerative effect of hepatocytes in rat.

• BMB Reports
• /
• 제57권2호
• /
• pp.98-103
• /
• 2024

The mammalian sirtuin family (SIRT1-SIRT7) has shown diverse biological roles in the regulation and maintenance of genome stability under genotoxic stress. SIRT7, one of the least studied sirtuin, has been demonstrated to be a key factor for DNA damage response (DDR). However, conflicting results have proposed that Sirt7 is an oncogenic factor to promote transformation in cancer cells. To address this inconsistency, we investigated properties of SIRT7 in hepatocellular carcinoma (HCC) regulation under DNA damage and found that loss of hepatic Sirt7 accelerated HCC progression. Specifically, the number, size, and volume of hepatic tumor colonies in diethylnitrosamine (DEN) injected Sirt7-deficient liver were markedly enhanced. Further, levels of HCC progression markers and pro-inflammatory cytokines were significantly elevated in the absence of hepatic Sirt7, unlike those in the control. In chromatin, SIRT7 was stabilized and colocalized to damage site by inhibiting the induction of γH2AX under DNA damage. Together, our findings suggest that SIRT7 is a crucial factor for DNA damage repair and that hepatic loss-of-Sirt7 can promote genomic instability and accelerate HCC development, unlike early studies describing that Sirt7 is an oncogenic factor.

• 대한방사선기술학회지:방사선기술과학
• /
• 제34권4호
• /
• pp.341-349
• /
• 2011

방사선치료를 위한 CT 검사 시 동일 환자에 대하여 3차원영상과, 호흡주기영상을 획득하기 위한 컴퓨터단층촬영에서 환자의 피폭선량을 측정하고자 SOMATON SENSATION OPEN(SIEMENS, GERMANY)을 이용하여 내원환자 중 폐암환자 10명, 간암환자 10명의 CT 검사 시 피폭선량을 측정했다. 환자가 받는 피폭선량은 The volume CT dose index(CTDIvol), Dose Length Product(DLP)를 이용하여 분석하였으며 각각의 장기들이 받는 피폭선량의 실측은 환자의 장기를 대상으로 할 수 없어 Rando 팬텀을 이용 흉부검사 시 폐와 심장, 척수를, 복부검사 시 간과 신장의 위치를 선택하여 in-vitro와 in-vivo 계측이 가능한 광유도발광선량계(Optically Stimulated Luminescent Dosimeter, Landauer, Inc., USA)를 이용하여 측정하였다. 폐암환자의 CT 검사 시 10명의 CTDIvol값은 5.7배, DLP값은 약 2.4배, 간암환자의 CTDIvol값은 3.8배, DLP값은 약 1.6배의 값을 나타내었고, OSLD를 이용한 실측정치 역시 폐암환자의 경우 6배, 간암환자의 경우 5.5배의 차이를 보이는 등 4DCT 검사에서 전체적인 피폭선량의 증가를 볼 수 있었다. 방사선치료 시 호흡에 의한 치료부위의 위치변화를 4DCT 검사를 이용하여 움직임을 보정하여 치료계획시 치료용적의 정확성을 높일 수 있으나 4DCT 검사로 인한 환자의 피폭선량 증가를 고려하여 검사시간과 검사범위를 줄여 피폭선량을 감소시키기 위한 노력이 필요하다.

• Journal of Chest Surgery
• /
• 제27권3호
• /
• pp.177-186
• /
• 1994

Pentastarch is a hydroxyethyl starch similar to hetastarch, but lower average molecular weight and fewer hydroxyethyl groups which result in enhanced enzymatic hydrolysis and faster renal elimination.This report was performed to compare the clinical efficacy and safety of 10 % pentastarch[Pentaspan , group I] for plasma volume expansion after open heart surgery with that of 5% albumin[Plasmanate, group II]. There were no statistically significant differences between the group I [n=18] and group II [n:19] in the preoperative parameters [age, sex, body weight] and operative parameters[bypass time, aorta cross clamping time]. During the first 24 hours after arrival of the patient in the surgical intensive care unit, colloid solution [500--1000 ml] was infused to maintain left atrial pressure of more than 8 mmHg, or cardiac index of 2.0 L/min/M2 of more. In results, there were 3 complications of hypotension immediately after infusion of 5 % albumin solution and 2 among the 3 patients were excluded for the study. However there was no complication after infusion of 10 % pentastarch solution. Hemodynamic responses to infusion was similar for both groups, although in group I a greater increase in both left atrial pressure[mean 1.8 versus 0.7 mmHg, p< 0.05] and right atrial pressure [mean 2.2 versus 1.7 mmHg, p < 0.05] was observed during infusion of the first 500 ml. There were no significant differences in any of the measured respiratory parameters[PaO2, intrapulmonary shunt, and effective lung compliance]. Homodilution with colloid significantly reduced hemoglobin [mean 1.2 versus 0.8 gm/dl], and serum protein and albumin level[total protein;4.8$\pm$ 0.5 versus 5.2 $\pm$0.5 gm/dl, p < 0.05: albumin: 3.2 $\pm$0.4 versus 3.6 $\pm$0.6 gm/dl, p < 0.05] by 6:00 AM on 1 day postoperatively, however there were no significant differences on 7 day postoperatively. The mean serum colloid osmotic pressure and osmolarity was similar in both group.There were no abnormal findings of liver function and kidney function in all the patients. There were no significant between-group differences in bleeding time, platelets, prothrombin time, activated partial thromboplastin time and amount of chest tube output measured on 1st and 7th postoperative day. These findings demonstrated that 10% pentastarch is more effective and safe for plasma volume expension than 5 % albumin solution with no adverse effects on coagulation. Also 10 % pentastarch is less expensive than 5 % albumin and it would appeare to be a reasonable first choice for plasma volume expansion.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권8호
• /
• pp.4711-4715
• /
• 2013

Aim: The aim of this study was to evaluate acute adverse events and efficacy of three-dimensional intensitymodulated radiotherapy (IMRT) combined with endocrine therapy for intermediate and advanced prostate cancer. Methods: Sixty-seven patients were treated with three-dimensional IMRT combined with maximum androgen blockade. The correlation between radiation-induced rectal injury and clinical factors was further analyzed. Results: After treatment, 21 patients had complete remission (CR), 37 had partial remission (PR), and nine had stable disease (SD), with an overall response rate of 86.5%. The follow-up period ranged from 12.5 to 99.6 months. Thirty-nine patients had a follow-up time of ${\geq}$ five years. In this group, three-year and five-year overall survival rates were 89% and 89.5%, respectively; three-year and five-year progression-free survival rates were 72% and 63%. In univariate analyses, gross tumor volume was found to be prognostic for survival ($X^2$ = 5.70, P = 0.037). Rates of leucopenia and anemia were 91.1% and 89.5%, respectively. Two patients developed acute liver injury, and a majority of patients developed acute radiation proctitis and cystitis, mainly grade 1/2. Tumor volume before treatment was the only prognostic factor influencing the severity of acute radiation proctitis (P < 0.05). Conclusions: IMRT combined with endocrine therapy demonstrated promising efficacy and was well tolerated in patients with intermediate and advanced prostate cancer.

• 약학회지
• /
• 제37권4호
• /
• pp.383-388
• /
• 1993

Pharmacokinetics of aucubin, an irdoid glucoside, was compared in rats of experimental hepatic failure(EHF). EHF was induced by CCI$_{4}$ or D-galactosamine pretreatment. This work was designed to find out any differences in the pharmacokinetics of aucubin that may explain the different protective effect of aucubin on CCI$_{4}$- and galactosamine-induced EHF : aucubin reportedly protected CCI$_{4}$-inducing hepatotoxicity effectively, but did not for galactosamine-hepatotoxicity. EHF was induced by intraperitoneal injection Of CCI$_{4}$(0.9ml/kg) or galactosamine(250 mg/kg) to Wistar rats 24 hr before the pharmacokinetic study. The rats were fasted during the 24 hr. Aucubin was iv injected at a dose of 15 mg/kg and the plasma aucubin was assayed by HPLC. There were no significant differences in the pathophysiologies(body weight, liver weight, GTP, hematocrit, blood cell distrbution and plasma protein binding of aucubin) between the two EHF models except GOP which was significantly (p<0.05) higher in CCI$_{4}$-than in galactosamine-EHF. On the other hand, pharmacokinetics of aucubin such as total cleatance(CL$_{t}$), distribution volume at steady-state(Vd$_{ss}$), and mean residence time(MRT) differed significantly(p<0.05) between the models : for example, CL$_{t}$ was increased two fold by CCI$_{4}$, but not by galaclosamine ; Vd$_{ss}$, in galactosamine-EHF was higher than that in CCI$_{4}$-EHF ; MRT was decreased by CCI$_{4}$, but increased conversely by galactosamine. The increase of CL$_{t}$(and decrease of MRT) in rats of CCI$_{4}$-EHF was contrary to the general expectation for the hepatic failure : most of the hepatic failures have been known to decrease CL$_{t}$ of the administered drugs. Whether the difference in the pharmacokinetics is responsible for the different protective effect of aucubin against the two EHF models is of interest. However, much more studies on biliary excretion, urinary excretion, and hepatic uptake in cellular level should be preceded before any conclusions are made on the role of different pharmacokinetics on the different pharmacology of aucubin.

• 핵의학기술
• /
• 제22권1호
• /
• pp.15-22
• /
• 2018

PET/MRI 검사 시 호흡에 의한 움직임은 영상의 질 저하는 물론 종양의 크기, 표준섭취계수의 오차를 발생시키는 원인이 된다. 본 연구에서는 일체형 PET/MRI 장비에서 MR기반 호흡 움직임 보정 방법의 적용에 따른 종양의 표준섭취계수, 크기와 영상 품질 변화를 평가하고자 하였다. Biograph mMR 3.0T (Siemens, Germany)장비에서 2016년 3월부터 7월까지 $^{18}F-FDG$ liver PET/MRI 검사를 시행한 30명 ($62.5{\pm}10.2$세)의 데이터를 분석하였다. 7분의 PET listmode 데이터를 획득하는 동안 MR 기반 호흡 움직임 보정 방법인 MAG, MTG와 NG T1 weighted MR 영상을 획득하였다. Gated PET 영상의 재구성은 35% efficiency window가 적용된 MAG와 MTG로부터 획득된 감쇄보정영상을 이용하여 시행하였다. Non-gate, MAG, MTG 영상에서 측정된 종양의 표준섭취계수와 Z축 방향의 크기 그리고 반치폭을 분석하였다 평균 $SUV_{max}$와 $SUV_{peak}$는 NG 대비 MAG 13.15%(P<0.0001), 8.66%(P<0.0001), MTG 13.27%(P<0.0001), 8.80%(P<0.0001) 증가하였으며 Z-축에서 평균 종양의 크기와 반치폭은 MAG 14.47%(P<0.0001), 15.49%(P=0.0004), MTG 14.89%(P<0.0001), 15.79%(P=0.0003) 감소하였으며 통계적으로 유의한 차이를 보였다. MAG와 MTG 비교 평가에서 MTG의 $SUV_{max}$와 $SUV_{peak}$는 MAG 대비 0.07%(P=0.8802), 0.13%(P=0.7766) 증가하였으며 Z-축에서 평균 종양의 크기와 반치폭은 0.49%(P=0.2786), 0.36%(P=0.2488) 감소하였다. 약 7분과 2분의 추가 검사시간이 필요한 MAG와 MTG에서 표준섭취계수와 종양의 크기, 반치폭에서 통계적으로 유의한 차이가 없었다. 간 PET/MRI 검사 시 MR 기반 호흡 움직임 보정 방법을 적용하였을 때 NG 대비 MAG, MTG 모두에서 표준섭취계수와 종양의 크기 및 공간분해능이 개선되었으며 MAG와 MTG의 결과 값은 통계적으로 유의한 차이가 없었다. 호흡에 의한 움직임에 영향을 받는 다양한 상 복부 검사에 MBRMCT를 적용 시 추가적인 장비의 설치 없이 약 2분의 추가 검사시간이 필요한 MTG 방법 적용하여 NG 대비 보다 정확한 정보를 제공할 수 있을 것으로 사료된다.

• 대한한의학방제학회지
• /
• 제6권1호
• /
• pp.119-139
• /
• 1998

간경변(肝硬變)은 각종(各種) 만성미만성간염(慢性彌滿性肝炎)이나 광범위(廣範圍)한 간장실질(肝臟實質)의 손상(損傷)이 계속적(繼續的)으로 발전(發展)하여 이루어진 결과(結果)이다. 주(主)된 병리적(病理的) 특징(特徵)은 간세포(肝細胞)의 변성(變成), 괴사(壞死) 후(後)에 나타나는 섬유조직(纖維組織)의 증식(增殖), 간세포(肝細胞)의 결절상(結節狀) 재생(再生), 가소엽(假小葉)의 형성(形成) 등(等)으로서, 이들 세가지의 변화(變化)가 뒤섞여 진행(進行) 되는 가운데, 간내(肝內) 혈관망(血管網)이 감소(減少)하거나 혈관망(血管網)에 이상(異狀) 함몰(陷沒)이 발생(發生)하는 것이다. 주(主)된 임상표현(臨床表現)은 간기능감퇴(肝機能減退)와 문맥압(門脈壓) 상승(上升)으로 인(因)한 비종대(脾腫大), 복수(腹水), 복벽정맥(腹壁靜脈)의 노장(怒張), 식도(食道)와 위저정맥(胃底靜脈)의 노장파열(怒張破裂), 간성혼수(肝性昏睡) 등(等)이 나타난다. 한의학(韓醫學)의 범주(範疇)로는 '적취(積聚), 징가, 황달(黃疸), 고창(鼓脹), 협통(脇痛), 단복창(單腹脹), 비괴' 등(等)에 해당(該當)되는 것으로 습열(濕熱)이 구울(久鬱)함에 따라 간(肝), 비(脾)가 손상(損傷)되고 이것이 더욱 오래되어 기체혈어(氣滯血瘀)로 발전(發展)하게 되는 병리변화(病理變化)를 갖는다. 이에 담도결찰(膽道結紮) 및 dimethylnitrosamine의 복강투여(腹腔投與)로 간경화(肝硬化)를 유발(誘發)하고, 울증(鬱證)에 다용하는 익국환과 익국보화환이 이러한 병증(病症)에 간기능보호작용(肝機能保護作用)이 있는가를 관찰(觀察)하고, 한의학적(韓醫學的) 병증(病症)의 분류(分類)에 따라 간질환(肝疾患)에 대(對)한 치료(治療)의 가능성(可能性)을 알아보고자 본(本) 실험(實驗)을 실시(實施)한 결과(結果), 유의성(有意性) 있는 결과(結果)를 얻었기에 보고(報告)하는 바이다.

• Tuberculosis and Respiratory Diseases
• /
• 제46권1호
• /
• pp.75-81
• /
• 1999

연구배경: 최근 상어 간유(squalene)에 의한 지방성 폐렴이 다수 보고되고 있으나 이에 대한 동물 실험이 미흡한 상태로 저자들은 토끼에서 상어 간유 흡인 후 나타나는 폐 반응을 HRCT와 병리학적 검사를 통해 알아보았다. 방 법: 14 마리의 백색 토끼를 대상으로 스쿠알렌을 흡인 시킨 후 12마리의 토끼를 4마리씩 각각 1주, 2주, 4주에 HRCT와 병리 소견을 관찰하였고, 나머지 2마리는 각각 흡인된 스쿠알렌 양을 달리하여 6주째에 관찰하였다, 결 과: 총 14마리중 l마리는 주입 즉시 즉사 하였으며 나머지 13 마리중 HRCT상 6마리에서 폐렴이 발생하였고, 1 주째에 기관지 공기 조영상을 동반한 광범위한 폐렴이 발생하였다가 4주째에는 폐용적 감소, 6 주째에는 기관지 확장소견이 동반되었다. 병리소견상 주로 기관지 주위에 심한 염증 소견을 보였고 1주째부터 격막비후 소견이 관찰되었고 2주째에 폐포내 대식세포수가 가장 많았으며 6주째에 섬유모세포의 증식이 관찰되었다. 곁 론: 스쿠알렌 흡인 후 폐렴이 발생하였으며, 이는 2-3주에 가장 심한 염증 소견을 보여, 이후 서서히 호전됨을 동물실험을 통해 증명하였으며, HRCT에서도 조직학적 소견과 유사한 소견을 관찰할 수 있었다.

• 한방재활의학과학회지
• /
• 제15권2호
• /
• pp.117-117
• /
• 2005

Objectives : This experimental study was designed to investigate the effect of SBY-III extract on the weight, cell size of epididymal fat-pad, fat accumulation area in liver, serum lipid level and UCP1 mRNA in brown adipose tissue of high fat diet-fed obese rats continued by high fat diet and regulated by normal Diet. Methods : The body weight gain, weight of the internal organs(epididymis, liver, brown adipose tissue), insulin, triglyceride, total cholesterol, total lopod, free fatty acid, expression of UCP1 mRNA were measured in high fat diet-fed obese rats continued by high fat diet and regulated by normal diet. The experimental study are divided into exp-I and exp-II. Each study was administered normal diet, high fat diet and SBY-III according to each situation. Normal group is normal diet for 8 weeks. Exp-I are divided into control group(high fat diet for 8 weeks) and sample group(high fat diet for 8 weeks and SBY-III for last 2 weeks). Exp-II are divided into control group(high fat diet for 6 weeks and normal diet for 2 weeks) and sample group(high fat diet for 6 weeks and normal diet with SBY-III for 2 weeks). These were then compared mutually. Results : 1. Irrespective of diet control, sample group taken SBY-III showed the more effective decrease of weight gain than control group and diet control-fed sample group with SBY-III showed the more effective decrease of weight loss including weight gain than control group. 2. Irrespective of diet control, sample group taken SBY-III showed the more effective decrease cell size of epididymal fat-pad, fat accumulation area in liver than control group. 3. Non diet control-fed sample group taken SBY-III showed the more effective decrease of serum triglyceride, total lipid, free fatty acid than control group and diet control-fed sample group taken SBY-III showed the decrease of serum triglyceride, free fatty acid than control group. 4. Only diet control-fed sample group taken SBY-III showed the decrease of UCP1 volume. Conclusions : These results shows that SBY-III has effects on anti-obesity, especially keeping pace with diet control.